尿激酶、肝素联合应用治疗进展型脑梗塞50例临床观察

目的：观察尿激酶与肝素联合应用治疗进展型脑梗塞的临床效果和安全性。方法；取治疗组和对照组，两组病例数相同，年龄相似，性别差异不大，有可比性。治疗组中50例用尿激酶20-30万单位，1-2天，肝素12500单位，5天；对照组用肝素12500单位，5天。开始用药时间均在发病5天之内，10h内症状有恶化。CT证实无出血，已有梗塞灶出现。治疗前及治疗后30天各MDS评分一次比较。结果：治疗组神经功能改善明显优于对照组，未见出血等不良反应。结论：中等剂量尿激酶与肝素合用治疗进展型缺血性脑梗塞，安全有效，值得推广应用。

Clinical Effects of Urokinase in Combination with Heparin Sodium in 50 Patients Suffer from Acute Cerebral Infarction

Purpose To assess the clinical efficacy and safety of acute cerebral progressive infarction cured with urokinase in combination with heparin sodium. Methods There were 50 cases in the control group and treated group. The treated group was treated with urokinase 300,000 units/day intravenous for 1~2 days, heparin sodium 12,500 units/day intravenous for 5 days, the control group was treated with heparin sodium 12,500 units/day intravenous for 5 days. All patients were treated within 5 days of onset and the deterioration of neurological deficits within 10 hours. The hypodensity was showed by brain CT scan without hemorrhage, MDS score was given before and after cure 30 days for comparison. Results The neurological deficits improvement in the treated group was more efficient than the control group and no hemorrhage was found. Conclusion Middle dose urokinase infusion in combination with heparin sodium intravenous in treatment of acute cerebral progressive infarction was safe and effective and showed obviously clinical valuable.